Cytokines and angiogenic factors in patients with metastatic renal cell carcinoma treated with interferon-α: Association of pretreatment serum levels with survival

Annals of Oncology

Volumn 20, Issue 10, 2009, Pages 1682-1687

  Montero, A J ^a,b   Diaz Montero, C M ^a,b   Millikan, R E ^a   Liu, J ^a   Do, K A ^a   Hodges, S ^a   Jonasch, E ^a   McIntyre, B W ^a   Hwu, P ^a   Tannir, N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Angiogenesis; Cytokine profiling; Inflammation; Interferon ; Metastatic renal cell carcinoma; Multiplex bead immunoassays

Indexed keywords

ALPHA INTERFERON; ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; CYTOKINE; INTERLEUKIN 12; INTERLEUKIN 5; INTERLEUKIN 6; PROTEIN P40; VASCULOTROPIN A;

ARTICLE; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KIDNEY CARCINOMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PREMEDICATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; SURVIVAL RATE; SURVIVAL TIME;

ANGIOGENESIS INDUCING AGENTS; CARCINOMA, RENAL CELL; CHI-SQUARE DISTRIBUTION; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROBLAST GROWTH FACTOR 2; FOLLOW-UP STUDIES; HUMANS; IMMUNOASSAY; INTERFERON-ALPHA; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-5; INTERLEUKIN-6; KAPLAN-MEIER ESTIMATE; MALE; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70349642288     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp054     Document Type: Article

References (25)

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N Engl J Med 2005; 353(23): 2477-2490.
2. Motzer RJ, Bacik J, Murphy BA et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20: 289-296.
3. Mekhail TM, Abou-Jawde RM, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
4. Diaz-Montero CM, Salem ML, Nishimura MI et al. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 2009; 58: 49-59.
5. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-726s.
6. Griffiths RW, Elkord E, Gilham DE et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007; 56: 1743-1753.
7. Almand B, Clark JI, Nikitina E et al. Increased production of immature myeloid cells in cancer patients: A mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689.
8. Rayman P, Wesa AK, Richmond AL et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 2004; 10: 6360S-6366S.
9. Jinushi M, Dranoff G. Triggering tumor immunity through angiogenesis targeting. Clin Cancer Res 2007; 13: 3762-3764.
10. Mantovani A, Romero P, Palucka AK, Marincola FM. Tumour immunity: effector response to tumour and role of the microenvironment. Lancet 2008; 371: 771-783.
11. Becker Y. Molecular immunological approaches to biotherapy of human cancers - a review, hypothesis and implications. Anticancer Res 2006; 26: 1113-1134.
12. Dredge K, Marriott JB, Todryk SM, Dalgleish AG. Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother 2002; 51: 521-531.
13. Budhu A, Forgues M, Ye QH et al. Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 2006; 10: 99-111.
14. Pellegrini P, Berghella AM, Del Beato T et al. Disregulation in TH1 and TH2 subsets of CD4+ T cells in peripheral blood of colorectal cancer patients and involvement in cancer establishment and progression. Cancer Immunol Immunother 1996; 42: 1-8.
15. Sparano A, Lathers DM, Achille N et al. Modulation of Th1 and Th2 cytokine profiles and their association with advanced head and neck squamous cell carcinoma. Otolaryngol Head Neck Surg 2004; 131: 573-576.
16. Gutterman JU. Cytokine therapeutics: Lessons from interferon alpha. Proc Natl Acad Sci U S A 1994; 91: 1198-1205.
17. Slaton JW, Perrotte P, Inoue K et al. Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 1999; 5: 2726-2734.
18. Tannir NM, Cohen L, Wang X et al. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 2006; 107: 2254-2261.
19. Tamhane AC, Dunloop DD. Statistics and Data Analysis: From Elementary to Intermediate. Upper Saddle River, NJ: Pearson Prentice-Hall 2000.
20. Breiman L, Friedman J, Stone CJ, Olshen RA. Classification and Regression Trees, 1st edition. Boca Raton, FL: Chapman & Hall 1984.
21. Venables WN, Ripley BD. Modern Applied Statistics with S-PLUS. New York, NY: Springer 1999.
22. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: Issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387.
23. Negrier S, Perol D, Menetrier-Caux C et al. Interleukin-6, interleukin-10, and vascular endothelial growth factor in metastatic renal cell carcinoma: Prognostic value of interleukin-6 - from the Groupe Francais d'Immunotherapie. J Clin Oncol 2004; 22: 2371-2378.
24. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007; 19: 209-216.
25. Callard R, George AJ, Stark J. Cytokines, chaos, and complexity. Immunity 1999; 11: 507-513.